RAREsummit19

Dr. DANIEL O’CONNOR

Medical Assessor, Medicines and Healthcare products Regulatory Agency, MHRA

Moderated Discussion: Disruptive innovation and transformation – Patients at the heart of the drug development process

Bio: Daniel is a Leicester medical graduate with a background in cancer research, histopathology and oncology. His PhD in the field of tumour suppressor genes was awarded from Imperial College London and he holds an MSc in Oncology from the Institute of Cancer Research. He completed higher medical training in the UK in Pharmaceutical Medicine. He joined the Medicines and Healthcare products Regulatory Agency (MHRA) as a Medical Assessor in 2006 from a clinical lecturer post at UCL/UCH/Ludwig Institute for Cancer Research.

He works in the licensing division of the MHRA. He is the UK representative on the Committee for Orphan Medicinal Products (COMP) and observer on the EMA’s Oncology Working Party. He is editor author of the first edition Oxford Specialist Handbook of Pharmaceutical Medicine and he is on the editorial board of the journal Expert Opinion on Orphan Drugs.